metformin has been researched along with Renal Insufficiency in 72 studies
Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.
Renal Insufficiency: Conditions in which the KIDNEYS perform below the normal level in the ability to remove wastes, concentrate URINE, and maintain ELECTROLYTE BALANCE; BLOOD PRESSURE; and CALCIUM metabolism. Renal insufficiency can be classified by the degree of kidney damage (as measured by the level of PROTEINURIA) and reduction in GLOMERULAR FILTRATION RATE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Use of the oral antidiabetic drug metformin may cause lactic acidosis, a rare but life-threatening complication, especially in patients with renal function loss." | 8.80 | [Prevention of lactic acidosis due to metformin intoxication in contrast media nephropathy]. ( de Bruin, TW; de Haan, M; Landewé-Cleuren, S; van Zwam, WH, 2000) |
| "Metformin associated lactic acidosis may potentially occur after combination with ribocilib, an uncommon but lethal complication from the interaction of these drugs, especially in patients who had preexisting renal impairment." | 8.12 | Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. ( Lagampan, C; Parinyanitikul, N; Poovorawan, N, 2022) |
| "The aim of this case report is to specify the frequency and mortality of Metformin-Associated Lactic Acidosis (MALA) in emergency medicine, as the diagnosis seems to occur more often than estimated." | 8.02 | Metformin Associated Lactic Acidosis in Clinical Practice - A Case Series. ( Kellerer, M; Schädle, P; Tschritter, O, 2021) |
| "To compare the risk of lactic acidosis hospitalization between patients treated with metformin versus sulfonylureas following development of reduced kidney function." | 7.96 | Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. ( Chipman, J; Chu, PY; Elasy, T; Greevy, RA; Griffin, MR; Grijalva, CG; Hackstadt, AJ; Hung, AM; Roumie, CL, 2020) |
| "To investigate whether the use of metformin during computed tomography (CT) with radiocontrast agents increases the risk of contrast-induced nephropathy (CIN) and metabolic acidosis after CT in type 2 diabetes patients with mild to moderate renal failure." | 7.91 | Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure? ( Baek, JH; Cho, HS; Cho, YY; Hahm, JR; Jung, J; Jung, JH; Kim, HS; Kim, KY; Kim, SK, 2019) |
| "Metformin-associated lactic acidosis (MALA) is a rare complication among patients who are diabetic, commonly presenting with non-specific findings, and developing mostly among those with other risk factors for lactic acidosis." | 7.88 | Metformin-associated lactic acidosis mimicking ischaemic bowel. ( Ali, S; Azarov, N; Hindi, Z; Labuschagne, H; Oud, L, 2018) |
| " There was no difference in prevalence of hyperlactatemia and lactic acidosis between the patients with and without metformin use (18." | 7.85 | Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. ( Cha, BS; Han, E; Hwang, S; Kang, ES; Kang, HP; Lee, BW; Lee, EY; Lee, HC; Lee, SH; Lee, W; Lee, YH; Lee, YM, 2017) |
| " Of 43 580 metformin and 37 788 other glucose-lowering agent users in northern Denmark and 102 688 metformin and 28 788 other glucose-lowering agent users in the UK during 2001-2011, we identified lactic acidosis using diagnostic codes." | 7.85 | Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK. ( Christiansen, CF; Ehrenstein, V; Gopalakrishnan, C; Heide-Jørgensen, U; Jick, S; Li, L; Nørrelund, H; Sørensen, HT, 2017) |
| "In conclusion, our findings support the low risk of MALA among patients with mild-to-moderate renal impairment and the likelihood of metformin to be an innocent bystander without a pathogenic role in the lactic acidosis in most cases." | 7.83 | Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease. ( Acikgoz, SB; Genc, AB; Nalbant, A; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M; Yilmaz, U, 2016) |
| "The crude incidence of lactic acidosis or elevated lactate concentrations in current metformin users was 7." | 7.80 | Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. ( De Smet, PA; de Vries, F; Derijks, HJ; Egberts, A; Eppenga, WL; Geerts, AF; Lalmohamed, A; Wensing, M, 2014) |
| "To determine whether the use of metformin in type 2 diabetic patients with various kidney functions is associated with an increased risk of lactic acidosis (LA)." | 7.80 | Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. ( Corvino, FA; Gottwald-Hostalek, U; Guedes, S; Richy, FF; Sabidó-Espin, M, 2014) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 7.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "Our data indicate that the incidence of metformin-associated lactic acidosis solely due to metformin accumulation is possible and underestimated." | 7.74 | Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? ( Felix, SB; Friesecke, S; Mayerle, J; Robinson, D; Roser, M; Runge, S; Warnke, C, 2008) |
| "We suspect that lactic acidosis may have been related to the use of metformin, the presence of heart and renal failure (contributing to metformin toxicity), and previous use of diclofenac sodium." | 7.73 | Metformin-associated lactic acidosis treated with continuous renal replacement therapy. ( Alivanis, P; Arvanitis, A; Giannikouris, I; Paliuras, C; Volanaki, M; Zervos, A, 2006) |
| " Doubling the metformin dose resulted in a 10-fold increase in mean blood levels and toxicity suggesting that the dosage range between therapeutic and toxic is narrow." | 5.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| "Metformin is a basic drug used for the treatment of type 2 diabetes mellitus." | 5.43 | [Chronic kidney diseases, metformin and lactic acidosis]. ( Borbély, Z, 2016) |
| "Numerous patients with type 2 diabetes have renal impairment, especially in the elderly population." | 5.39 | [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. ( Scheen, AJ, 2013) |
| "There is no evidence that the use of contrast media (CM) in diabetic patients with serum creatinine <130 μmole/L leads to metformin accumulation and subsequent lactic acidosis." | 5.15 | Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry. ( Al Babtain, MA; Al Taweel, ES; Al-Amri, HS; Al-Moghairi, AM; Aloudah, NM; Radwan, MA, 2011) |
| "Metformin has been associated with lactic acidosis." | 4.95 | Lactate Levels with Chronic Metformin Use: A Narrative Review. ( Castelino, RL; Huang, W; Peterson, GM, 2017) |
| "For fear of lactic acidosis the currently listed contraindications to the use of metformin exclude a large number of people with type 2 diabetes from efficacious anti-hyperglycemic and cardioprotective treatment." | 4.83 | [Traditional contraindications to the use of metformin -- more harmful than beneficial?]. ( Egberts, EH; Holstein, A, 2006) |
| "Use of the oral antidiabetic drug metformin may cause lactic acidosis, a rare but life-threatening complication, especially in patients with renal function loss." | 4.80 | [Prevention of lactic acidosis due to metformin intoxication in contrast media nephropathy]. ( de Bruin, TW; de Haan, M; Landewé-Cleuren, S; van Zwam, WH, 2000) |
| " We sought to determine the effect of metformin, dipeptidyl peptidase-4 inhibitors (DPP-4i), and insulin on admission to the intensive care unit (ICU), need for assisted ventilation, development of renal insufficiency, and mortality in patients admitted with COVID-19 infection after controlling for clinical variables and other relevant diabetes-related medications in patients with type 2 diabetes mellitus (DM)." | 4.31 | Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019-Related Hospital Outcomes in Patients with Type 2 Diabetes. ( Alwakeel, M; Bena, J; Buehler, L; Lansang, MC; Makin, V; Obiri-Yeboah, D; Pantalone, KM; Zhou, K, 2023) |
| "Metformin associated lactic acidosis may potentially occur after combination with ribocilib, an uncommon but lethal complication from the interaction of these drugs, especially in patients who had preexisting renal impairment." | 4.12 | Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report. ( Lagampan, C; Parinyanitikul, N; Poovorawan, N, 2022) |
| "The aim of this case report is to specify the frequency and mortality of Metformin-Associated Lactic Acidosis (MALA) in emergency medicine, as the diagnosis seems to occur more often than estimated." | 4.02 | Metformin Associated Lactic Acidosis in Clinical Practice - A Case Series. ( Kellerer, M; Schädle, P; Tschritter, O, 2021) |
| "To compare the risk of lactic acidosis hospitalization between patients treated with metformin versus sulfonylureas following development of reduced kidney function." | 3.96 | Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. ( Chipman, J; Chu, PY; Elasy, T; Greevy, RA; Griffin, MR; Grijalva, CG; Hackstadt, AJ; Hung, AM; Roumie, CL, 2020) |
| "To investigate whether the use of metformin during computed tomography (CT) with radiocontrast agents increases the risk of contrast-induced nephropathy (CIN) and metabolic acidosis after CT in type 2 diabetes patients with mild to moderate renal failure." | 3.91 | Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure? ( Baek, JH; Cho, HS; Cho, YY; Hahm, JR; Jung, J; Jung, JH; Kim, HS; Kim, KY; Kim, SK, 2019) |
| "Metformin-associated lactic acidosis (MALA) is a rare complication among patients who are diabetic, commonly presenting with non-specific findings, and developing mostly among those with other risk factors for lactic acidosis." | 3.88 | Metformin-associated lactic acidosis mimicking ischaemic bowel. ( Ali, S; Azarov, N; Hindi, Z; Labuschagne, H; Oud, L, 2018) |
| " As the risk of inducing lactic acidosis is very low in connection with administration of iodine contrast media, new recommendations in Sweden say that metformin must be stopped only when GFR is below 45 mL/min." | 3.88 | [Treatment with metformin in type 2 diabetes mellitus - new routines when renal function is reduced and in connection with administration of iodine contrast media]. ( Frid, A; Sterner, G, 2018) |
| " Of 43 580 metformin and 37 788 other glucose-lowering agent users in northern Denmark and 102 688 metformin and 28 788 other glucose-lowering agent users in the UK during 2001-2011, we identified lactic acidosis using diagnostic codes." | 3.85 | Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK. ( Christiansen, CF; Ehrenstein, V; Gopalakrishnan, C; Heide-Jørgensen, U; Jick, S; Li, L; Nørrelund, H; Sørensen, HT, 2017) |
| " There was no difference in prevalence of hyperlactatemia and lactic acidosis between the patients with and without metformin use (18." | 3.85 | Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes. ( Cha, BS; Han, E; Hwang, S; Kang, ES; Kang, HP; Lee, BW; Lee, EY; Lee, HC; Lee, SH; Lee, W; Lee, YH; Lee, YM, 2017) |
| "In conclusion, our findings support the low risk of MALA among patients with mild-to-moderate renal impairment and the likelihood of metformin to be an innocent bystander without a pathogenic role in the lactic acidosis in most cases." | 3.83 | Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease. ( Acikgoz, SB; Genc, AB; Nalbant, A; Sipahi, S; Solak, Y; Tamer, A; Yildirim, M; Yilmaz, U, 2016) |
| "Overdosing of the oral antidiabetic metformin in impaired renal function is an important contributory cause to life-threatening lactic acidosis." | 3.83 | Development, implementation and outcome analysis of semi-automated alerts for metformin dose adjustment in hospitalized patients with renal impairment. ( Bucklar, G; Gött, C; Jödicke, A; Krattinger, R; Niedrig, D; Russmann, S, 2016) |
| "To determine whether the use of metformin in type 2 diabetic patients with various kidney functions is associated with an increased risk of lactic acidosis (LA)." | 3.80 | Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study. ( Corvino, FA; Gottwald-Hostalek, U; Guedes, S; Richy, FF; Sabidó-Espin, M, 2014) |
| "The crude incidence of lactic acidosis or elevated lactate concentrations in current metformin users was 7." | 3.80 | Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study. ( De Smet, PA; de Vries, F; Derijks, HJ; Egberts, A; Eppenga, WL; Geerts, AF; Lalmohamed, A; Wensing, M, 2014) |
| "The reported incidence of metformin associated lactic acidosis (MALA) in type 2 diabetes mellitus (DM) is 3-9 cases per 100,000 patient-years." | 3.77 | Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements. ( Doorenbos, CJ; van Berlo-van de Laar, IR; Vermeij, CG, 2011) |
| "Our data indicate that the incidence of metformin-associated lactic acidosis solely due to metformin accumulation is possible and underestimated." | 3.74 | Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation? ( Felix, SB; Friesecke, S; Mayerle, J; Robinson, D; Roser, M; Runge, S; Warnke, C, 2008) |
| " This is largely due to the historical experience of lactic acidosis with phenformin, despite the fact that metformin does not predispose to this when compared with other therapies." | 3.73 | Contraindications can damage your health--is metformin a case in point? ( Holstein, A; Stumvoll, M, 2005) |
| "We suspect that lactic acidosis may have been related to the use of metformin, the presence of heart and renal failure (contributing to metformin toxicity), and previous use of diclofenac sodium." | 3.73 | Metformin-associated lactic acidosis treated with continuous renal replacement therapy. ( Alivanis, P; Arvanitis, A; Giannikouris, I; Paliuras, C; Volanaki, M; Zervos, A, 2006) |
| "Intravascular administration of iodinated contrast media to patients who are receiving metformin, an oral antidiabetic agent, can result in lactic acidosis." | 3.70 | Metformin and contrast media: where is the conflict? ( Hammond, DI; Rasuli, P, 1998) |
| "Metformin is contraindicated in patients with renal impairment; however, there is poor adherence to current dosing guidelines." | 2.78 | Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function. ( Arora, M; Day, RO; Duong, JK; Furlong, TJ; Graham, GG; Greenfield, JR; Greenup, LC; Kirkpatrick, CM; Kumar, SS; Lee, TC; Timmins, P; Williams, KM, 2013) |
| "Hypoglycemia is a frequent adverse effect of treatment with sulfonylurea, glinides, or insulin in older adults with diabetes." | 2.49 | [Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes]. ( Aso, Y; Jojima, T, 2013) |
| " The elimination half-life (t(½)) of metformin during multiple dosages in patients with good renal function is approximately 5 hours." | 2.47 | Clinical pharmacokinetics of metformin. ( Arora, M; Day, RO; Doogue, MP; Duong, JK; Furlong, TJ; Graham, GG; Greenfield, JR; Greenup, LC; Kirkpatrick, CM; Punt, J; Ray, JE; Timmins, P; Williams, KM, 2011) |
| " Metformin has an absolute oral bioavailability of 40 to 60%, and gastrointestinal absorption is apparently complete within 6 hours of ingestion." | 2.39 | Clinical pharmacokinetics of metformin. ( Scheen, AJ, 1996) |
| " Doubling the metformin dose resulted in a 10-fold increase in mean blood levels and toxicity suggesting that the dosage range between therapeutic and toxic is narrow." | 1.91 | Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease. ( Atwood, DJ; Chaudhary, A; Edelstein, CL; He, Z; Li, AS; Oto, OA; Wempe, MF, 2023) |
| "A total of 1086 patients with type 2 diabetes were included." | 1.72 | Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective. ( Bai, J; Cheng, X; Dong, LM; Liu, J; Luo, SQ; Song, ZH; Wang, XF; Wang, XL; Xu, SS; Zhang, C; Zhou, JB, 2022) |
| "Metformin has both hypoglycaemic effects and reno-protection ability." | 1.48 | Metabolic profiling of metformin treatment for low-level Pb-induced nephrotoxicity in rat urine. ( Chen, SM; Huang, YS; Lee, JA; Wang, SH, 2018) |
| "Metformin is a basic drug used for the treatment of type 2 diabetes mellitus." | 1.43 | [Chronic kidney diseases, metformin and lactic acidosis]. ( Borbély, Z, 2016) |
| " Metformin may be used safely when renal function is poor provided dosage is appropriately reduced." | 1.43 | Trends in metformin utilisation and dose appropriateness in Australia. ( Baysari, MT; Chen, W; Day, RO; Graham, GG; Greenfield, JR; Kumar, SS; Moon, J; Viardot, A; Williams, KM, 2016) |
| "Metformin is a biguanaide antidiabetic drug used worldwide, and its effectiveness and benefits have already been established." | 1.43 | Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin. ( Hiraoka, S; Nishihara, M; Tsuji, H; Yokoyama, S, 2016) |
| "Incidence of recurrences was high (38%), and increasing body mass index was the only predictor of relapse." | 1.42 | Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland postpericardiotomy syndrome study. ( Airaksinen, J; Gunn, J; Karjalainen, P; Kiviniemi, T; Lehto, J, 2015) |
| "A model that incorporates HbA1c and diabetes complications can serve as a useful clinical decision tool for selection of treatment options." | 1.40 | Second-line agents for glycemic control for type 2 diabetes: are newer agents better? ( Denton, BT; Mason, JE; McCoy, RG; Shah, ND; Smith, SA; Zhang, Y, 2014) |
| "Metformin is an oral antihyperglycemic agent used in the management of type 2 diabetes mellitus." | 1.40 | Fatal metformin overdose: case report and postmortem biochemistry contribution. ( Bonsignore, A; Fraternali Orcioni, G; Palmiere, C; Pozzi, F; Ventura, F, 2014) |
| " Almost 5 years after its launch in Belgium, the present review summarizes the most recent data regarding the clinical efficacy of this antidiabetic agent, the controversy about its safety profile, its use at lower dosage in case of moderate to severe renal insufficiency, the various indications that have been successively accepted and reimbursed, and, finally, the perspectives offered by a large ongoing cardiovascular outcome trial (TECOS)." | 1.39 | [Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation]. ( Scheen, AJ; Van Gaal, LF, 2013) |
| "Numerous patients with type 2 diabetes have renal impairment, especially in the elderly population." | 1.39 | [How I treat ... with metformin a diabetic patient with moderate renal insufficiency]. ( Scheen, AJ, 2013) |
| " Pharmacokinetic studies have demonstrated a similar bioavailability of M-ER administered once daily to immediate-release metformin given twice daily." | 1.35 | Clinical development of metformin extended-release tablets for type 2 diabetes: an overview. ( Cowles, VE; Cramer, M; Gordi, T; Heritier, M; Hou, E; Schwartz, SL, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (5.56) | 18.2507 |
| 2000's | 19 (26.39) | 29.6817 |
| 2010's | 35 (48.61) | 24.3611 |
| 2020's | 14 (19.44) | 2.80 |
| Authors | Studies |
|---|---|
| Lagampan, C | 1 |
| Poovorawan, N | 1 |
| Parinyanitikul, N | 1 |
| Slahor, L | 2 |
| Theurey, P | 1 |
| Vial, G | 1 |
| Fontaine, E | 1 |
| Monternier, PA | 1 |
| Fouqueray, P | 1 |
| Bolze, S | 1 |
| Moller, DE | 1 |
| Hallakou-Bozec, S | 1 |
| Song, ZH | 1 |
| Wang, XL | 1 |
| Wang, XF | 1 |
| Liu, J | 1 |
| Luo, SQ | 1 |
| Xu, SS | 1 |
| Cheng, X | 1 |
| Bai, J | 1 |
| Dong, LM | 1 |
| Zhang, C | 1 |
| Zhou, JB | 1 |
| Hai, PD | 3 |
| Thu, NT | 3 |
| Phuong, LL | 3 |
| Manh, NV | 3 |
| Hoa, LTV | 3 |
| Obiri-Yeboah, D | 1 |
| Bena, J | 1 |
| Alwakeel, M | 1 |
| Buehler, L | 1 |
| Makin, V | 1 |
| Zhou, K | 1 |
| Pantalone, KM | 1 |
| Lansang, MC | 1 |
| Oto, OA | 1 |
| Atwood, DJ | 1 |
| Chaudhary, A | 1 |
| He, Z | 1 |
| Li, AS | 1 |
| Wempe, MF | 1 |
| Edelstein, CL | 1 |
| Mordi, IR | 1 |
| Mohan, M | 1 |
| Lang, CC | 1 |
| Bergmark, BA | 1 |
| Bhatt, DL | 1 |
| McGuire, DK | 1 |
| Scirica, BM | 1 |
| Chu, PY | 1 |
| Hackstadt, AJ | 1 |
| Chipman, J | 1 |
| Griffin, MR | 1 |
| Hung, AM | 1 |
| Greevy, RA | 1 |
| Grijalva, CG | 1 |
| Elasy, T | 1 |
| Roumie, CL | 1 |
| Elsisi, GH | 1 |
| Anwar, MM | 1 |
| Khattab, M | 1 |
| Elebrashy, I | 1 |
| Wafa, A | 1 |
| Elhadad, H | 1 |
| Awad, M | 1 |
| Carapinha, JL | 1 |
| Schädle, P | 1 |
| Tschritter, O | 1 |
| Kellerer, M | 1 |
| Posma, RA | 1 |
| Hulman, A | 1 |
| Thomsen, RW | 1 |
| Jespersen, B | 1 |
| Nijsten, MW | 1 |
| Christiansen, CF | 2 |
| Huang, W | 1 |
| Castelino, RL | 1 |
| Peterson, GM | 1 |
| Khan, M | 1 |
| Siddiqui, N | 1 |
| Oktay, V | 1 |
| Calpar Çıralı, İ | 1 |
| Sinan, ÜY | 1 |
| Yıldız, A | 1 |
| Ersanlı, MK | 1 |
| Ali, S | 1 |
| Labuschagne, H | 1 |
| Azarov, N | 1 |
| Hindi, Z | 1 |
| Oud, L | 1 |
| Sterner, G | 1 |
| Frid, A | 1 |
| Huang, YS | 1 |
| Wang, SH | 1 |
| Chen, SM | 1 |
| Lee, JA | 1 |
| Scheen, AJ | 4 |
| Lefèbvre, PJ | 1 |
| Paquot, N | 1 |
| Jung, J | 1 |
| Cho, YY | 1 |
| Jung, JH | 1 |
| Kim, KY | 1 |
| Kim, HS | 1 |
| Baek, JH | 1 |
| Hahm, JR | 1 |
| Cho, HS | 1 |
| Kim, SK | 1 |
| Duong, JK | 2 |
| Kumar, SS | 2 |
| Kirkpatrick, CM | 2 |
| Greenup, LC | 2 |
| Arora, M | 2 |
| Lee, TC | 1 |
| Timmins, P | 2 |
| Graham, GG | 3 |
| Furlong, TJ | 2 |
| Greenfield, JR | 3 |
| Williams, KM | 3 |
| Day, RO | 3 |
| Bonsignore, A | 1 |
| Pozzi, F | 1 |
| Fraternali Orcioni, G | 1 |
| Ventura, F | 1 |
| Palmiere, C | 1 |
| Van Gaal, LF | 1 |
| Jojima, T | 1 |
| Aso, Y | 1 |
| Zhang, Y | 1 |
| McCoy, RG | 1 |
| Mason, JE | 1 |
| Smith, SA | 1 |
| Shah, ND | 1 |
| Denton, BT | 1 |
| Lalau, JD | 1 |
| Arnouts, P | 1 |
| Sharif, A | 2 |
| De Broe, ME | 1 |
| Eppenga, WL | 1 |
| Lalmohamed, A | 1 |
| Geerts, AF | 1 |
| Derijks, HJ | 1 |
| Wensing, M | 1 |
| Egberts, A | 1 |
| De Smet, PA | 1 |
| de Vries, F | 1 |
| Richy, FF | 1 |
| Sabidó-Espin, M | 1 |
| Guedes, S | 1 |
| Corvino, FA | 1 |
| Gottwald-Hostalek, U | 1 |
| Flory, JH | 1 |
| Hennessy, S | 1 |
| Lehto, J | 1 |
| Gunn, J | 1 |
| Karjalainen, P | 1 |
| Airaksinen, J | 1 |
| Kiviniemi, T | 1 |
| Weinrauch, LA | 1 |
| D'Elia, JA | 1 |
| Finn, P | 1 |
| Lewis, EF | 1 |
| Desai, AS | 1 |
| Claggett, BL | 1 |
| Cooper, ME | 1 |
| McGill, JB | 1 |
| Sipahi, S | 1 |
| Solak, Y | 1 |
| Acikgoz, SB | 1 |
| Genc, AB | 1 |
| Yildirim, M | 1 |
| Yilmaz, U | 1 |
| Nalbant, A | 1 |
| Tamer, A | 1 |
| Wright, JJ | 1 |
| Tylee, TS | 1 |
| Borbély, Z | 1 |
| Niedrig, D | 1 |
| Krattinger, R | 1 |
| Jödicke, A | 1 |
| Gött, C | 1 |
| Bucklar, G | 1 |
| Russmann, S | 1 |
| Li, L | 1 |
| Jick, S | 1 |
| Gopalakrishnan, C | 1 |
| Heide-Jørgensen, U | 1 |
| Nørrelund, H | 1 |
| Sørensen, HT | 1 |
| Ehrenstein, V | 1 |
| Moon, J | 1 |
| Baysari, MT | 1 |
| Chen, W | 1 |
| Viardot, A | 1 |
| Visconti, L | 1 |
| Cernaro, V | 1 |
| Ferrara, D | 1 |
| Costantino, G | 1 |
| Aloisi, C | 1 |
| Amico, L | 1 |
| Chirico, V | 1 |
| Santoro, D | 1 |
| Noto, A | 1 |
| David, A | 1 |
| Buemi, M | 1 |
| Lacquaniti, A | 1 |
| Yokoyama, S | 1 |
| Tsuji, H | 1 |
| Hiraoka, S | 1 |
| Nishihara, M | 1 |
| Lee, EY | 1 |
| Hwang, S | 1 |
| Lee, YH | 1 |
| Lee, SH | 1 |
| Lee, YM | 1 |
| Kang, HP | 1 |
| Han, E | 1 |
| Lee, W | 1 |
| Lee, BW | 1 |
| Kang, ES | 1 |
| Cha, BS | 1 |
| Lee, HC | 1 |
| Schwartz, SL | 1 |
| Gordi, T | 1 |
| Hou, E | 1 |
| Cramer, M | 1 |
| Heritier, M | 1 |
| Cowles, VE | 1 |
| Molina Infante, J | 1 |
| Prieto Bermejo, AB | 1 |
| Pérez Gallardo, B | 1 |
| Fernández Bermejo, M | 1 |
| Punt, J | 1 |
| Doogue, MP | 1 |
| Ray, JE | 1 |
| van Berlo-van de Laar, IR | 1 |
| Vermeij, CG | 1 |
| Doorenbos, CJ | 1 |
| Lipska, KJ | 1 |
| Bailey, CJ | 1 |
| Inzucchi, SE | 1 |
| Radwan, MA | 1 |
| Al Taweel, ES | 1 |
| Al-Moghairi, AM | 1 |
| Aloudah, NM | 1 |
| Al Babtain, MA | 1 |
| Al-Amri, HS | 1 |
| Phillips, P | 1 |
| Braddon, J | 1 |
| Cayley, WE | 1 |
| Heine, RJ | 1 |
| Nisbet, JC | 1 |
| Sturtevant, JM | 1 |
| Prins, JB | 1 |
| King, JE | 1 |
| McCormack, J | 1 |
| Johns, K | 1 |
| Tildesley, H | 1 |
| Holstein, A | 2 |
| Stumvoll, M | 1 |
| Egberts, EH | 1 |
| Hemmelder, MH | 1 |
| Hoogendoorn, M | 1 |
| Halma, C | 1 |
| Alivanis, P | 1 |
| Giannikouris, I | 1 |
| Paliuras, C | 1 |
| Arvanitis, A | 1 |
| Volanaki, M | 1 |
| Zervos, A | 1 |
| Rigalleau, V | 1 |
| Lasseur, C | 1 |
| Beauvieux, MC | 1 |
| Chauveau, P | 1 |
| Raffaitin, C | 1 |
| Perlemoine, C | 1 |
| Barthe, N | 1 |
| Combe, C | 1 |
| Gin, H | 1 |
| Runge, S | 1 |
| Mayerle, J | 1 |
| Warnke, C | 1 |
| Robinson, D | 1 |
| Roser, M | 1 |
| Felix, SB | 1 |
| Friesecke, S | 1 |
| Jain, V | 1 |
| Sharma, D | 1 |
| Prabhakar, H | 1 |
| Dash, HH | 1 |
| Chen, J | 1 |
| Alemao, E | 1 |
| Yin, D | 1 |
| Cook, J | 1 |
| Connolly, V | 1 |
| Kesson, CM | 1 |
| Harrower, AD | 1 |
| Rasuli, P | 1 |
| Hammond, DI | 1 |
| Landewé-Cleuren, S | 1 |
| van Zwam, WH | 1 |
| de Bruin, TW | 1 |
| de Haan, M | 1 |
| Henry, WD | 1 |
| Horlen, C | 1 |
| Malone, R | 1 |
| Bryant, B | 1 |
| Dennis, B | 1 |
| Carey, T | 1 |
| Pignone, M | 1 |
| Rothman, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Safety and Efficacy of Adding Dapagliflozin and Furosemide in Diabetic Patients (Type 2) With Decompensated Heart Failure With Reduced Ejection Fraction (HFrEF)[NCT04385589] | Phase 4 | 100 participants (Actual) | Interventional | 2020-05-01 | Completed | ||
| Metformin Continuation Versus Interruption Following Coronary Angiography: a Pilot Randomized Controlled Trial[NCT03980990] | Phase 4 | 500 participants (Anticipated) | Interventional | 2019-06-17 | Recruiting | ||
| A Prospective, Randomized Open-Label Phase II Study of the Safety and Tolerability of Metformin in Combination With Standard Antimicrobial Treatment of Pulmonary Tuberculosis in People With TB and Co-infected With HIV[NCT04930744] | Phase 2 | 112 participants (Anticipated) | Interventional | 2021-08-03 | Recruiting | ||
| Effect of the Administration of Melatonin and Metformin on Glycemic Control, Genotoxicity and Cytotoxicity Markers in Patients With Prediabetes: Pilot Study[NCT03848533] | Phase 2 | 42 participants (Anticipated) | Interventional | 2019-08-22 | Recruiting | ||
| A Clinical Trial to Evaluate the Effect of Nilotinib on the Pharmacokinetics and Pharmacodynamics of Metformin in Healthy Male Adults[NCT04448821] | Phase 1 | 16 participants (Actual) | Interventional | 2020-07-23 | Completed | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| Use of Metformin in Prevention and Treatment of Cardiac Fibrosis in PAI-1 Deficient Population[NCT05317806] | Phase 4 | 15 participants (Anticipated) | Interventional | 2022-10-10 | Active, not recruiting | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| A Combined Single Dose Study Under Fasting Condition And Multiple Doses Study Under Normal Diabetic Meal Comparing the Bioavailability of Two Formulations of 500 mg Metformin Hydrochloride Extended Release Tablets.[NCT01677260] | 38 participants (Actual) | Interventional | 2009-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
14 reviews available for metformin and Renal Insufficiency
| Article | Year |
|---|---|
Lactate Levels with Chronic Metformin Use: A Narrative Review.
Topics: Acidosis, Lactic; Humans; Hypoglycemic Agents; Incidence; Lactic Acid; Metformin; Renal Insufficienc | 2017 |
[Attention to the use of oral anti-diabetic medication in older adults with type 2 diabetes].
Topics: Cognition Disorders; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Humans; Hypoglyc | 2013 |
Metformin and other antidiabetic agents in renal failure patients.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dipeptidyl-Peptidase IV Inhibit | 2015 |
In brief: New recommendations for use of metformin in renal impairment.
Topics: Animals; Drug Labeling; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Metformin; Renal In | 2016 |
Pharmacologic Therapy of Type 2 Diabetes.
Topics: Aging; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dr | 2016 |
Metformin-related lactic acidosis: is it a myth or an underestimated reality?
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Renal Insuffici | 2016 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Biological Availability; Blood Glucose; Diabetes Mellitus, Type 2; Half-Life; | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Use of metformin in the setting of mild-to-moderate renal insufficiency.
Topics: Acidosis, Lactic; Contraindications; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtr | 2011 |
Oral hypoglycaemics. When not to use what.
Topics: Acarbose; Acidosis, Lactic; Aged; Contraindications; Diabetes Mellitus, Type 2; Female; Glyburide; H | 2002 |
Metformin's contraindications should be contraindicated.
Topics: Acidosis, Lactic; Age Factors; Aged; Aged, 80 and over; Contraindications; Diabetes Mellitus, Type 2 | 2005 |
[Traditional contraindications to the use of metformin -- more harmful than beneficial?].
Topics: Acidosis, Lactic; Age Factors; Contraindications; Diabetes Mellitus, Type 2; Drug Interactions; Hear | 2006 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inj | 1996 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inj | 1996 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inj | 1996 |
Clinical pharmacokinetics of metformin.
Topics: Administration, Oral; Diabetes Mellitus, Type 2; Drug Interactions; Humans; Hypoglycemic Agents; Inj | 1996 |
Pharmacokinetics of oral antihyperglycaemic agents in patients with renal insufficiency.
Topics: Acarbose; Administration, Oral; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; R | 1996 |
[Prevention of lactic acidosis due to metformin intoxication in contrast media nephropathy].
Topics: Acidosis, Lactic; Clinical Protocols; Contraindications; Contrast Media; Creatinine; Diabetes Mellit | 2000 |
4 trials available for metformin and Renal Insufficiency
| Article | Year |
|---|---|
Impact of continuation of metformin prior to elective coronary angiography on acute contrast nephropathy in patients with normal or mildly impaired renal functions.
Topics: Contrast Media; Coronary Angiography; Creatinine; Diabetes Mellitus, Type 2; Drug Administration Sch | 2017 |
Population pharmacokinetics of metformin in healthy subjects and patients with type 2 diabetes mellitus: simulation of doses according to renal function.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Delayed-Action Preparations; Diabetes Mellitus, Type 2; | 2013 |
Strategies for glucose control in a study population with diabetes, renal disease and anemia (Treat study).
Topics: Aged; Anemia; Australia; Blood Glucose; Diabetes Mellitus, Type 2; Europe; Female; Humans; Hypoglyce | 2016 |
Monitoring metformin in cardiac patients exposed to contrast media using ultra-high-performance liquid chromatography tandem mass-spectrometry.
Topics: Acidosis, Lactic; Cardiac Catheterization; Chromatography, High Pressure Liquid; Contrast Media; Cre | 2011 |
54 other studies available for metformin and Renal Insufficiency
| Article | Year |
|---|---|
Lactic acidosis, a potential toxicity from drug-drug interaction related to concomitant ribociclib and metformin in preexisting renal insufficiency: A case report.
Topics: Acidosis, Lactic; Aminopyridines; Breast Neoplasms; Drug Interactions; Female; Fulvestrant; Humans; | 2022 |
[CME: Metformin - Dos and Don'ts].
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Renal Insuffici | 2021 |
[CME/Answers: Metformin - Dos and Don'ts].
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Renal Insuffici | 2022 |
Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin.
Topics: Acidosis, Lactic; Animals; Diabetes Mellitus, Type 2; Dogs; Humans; Hypoglycemic Agents; Lactic Acid | 2022 |
Gaps of Medication Treatment Management Between Guidelines and Real-World for Inpatients With Type 2 Diabetes in China From Pharmacist's Perspective.
Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cholesterol, LDL; Cross- | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Unusual Case of Metformin-Associated Lactic Acidosis in Patient with Type 2 Diabetes Mellitus.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus, Type 2; Humans; Male; Metformin; Renal Dialysis; Renal In | 2022 |
Association of Metformin, Dipeptidyl Dipeptidase-4 Inhibitors, and Insulin with Coronavirus Disease 2019-Related Hospital Outcomes in Patients with Type 2 Diabetes.
Topics: COVID-19; Diabetes Mellitus, Type 2; Dipeptidases; Dipeptidyl-Peptidase IV Inhibitors; Glycated Hemo | 2023 |
Metformin does not slow cyst growth in the PCK rat model of polycystic kidney disease.
Topics: AMP-Activated Protein Kinases; Animals; Cysts; Humans; Lactates; Male; Metformin; Polycystic Kidney | 2023 |
Letter by Mordi et al Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
Topics: Diabetes Mellitus; Heart Failure; Humans; Metformin; Renal Insufficiency | 2020 |
Response by Bergmark et al to Letter Regarding Article, "Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial".
Topics: Diabetes Mellitus; Heart Failure; Humans; Metformin; Renal Insufficiency | 2020 |
Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas.
Topics: Acidosis, Lactic; Aged; Cohort Studies; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Female; G | 2020 |
Budget impact analysis for dapagliflozin in type 2 diabetes in Egypt.
Topics: Benzhydryl Compounds; Budgets; Cardiovascular Diseases; Cost-Benefit Analysis; Diabetes Mellitus, Ty | 2020 |
Metformin Associated Lactic Acidosis in Clinical Practice - A Case Series.
Topics: Acidosis, Lactic; Aged; Comorbidity; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Humans; H | 2021 |
Metformin use and early lactate levels in critically ill patients according to chronic and acute renal impairment.
Topics: Aged; Critical Illness; Denmark; Female; Humans; Hypoglycemic Agents; Lactic Acid; Male; Metformin; | 2020 |
Metformin use in renal disease.
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Renal Insuffici | 2017 |
Metformin-associated lactic acidosis mimicking ischaemic bowel.
Topics: Abdominal Pain; Acidosis, Lactic; Aged; Diabetes Mellitus; Diagnosis, Differential; Emergency Medica | 2018 |
[Treatment with metformin in type 2 diabetes mellitus - new routines when renal function is reduced and in connection with administration of iodine contrast media].
Topics: Acidosis, Lactic; Body Size; Contrast Media; Diabetes Mellitus, Type 2; Female; Glomerular Filtratio | 2018 |
Metabolic profiling of metformin treatment for low-level Pb-induced nephrotoxicity in rat urine.
Topics: Administration, Oral; Animals; Biological Factors; Disease Models, Animal; Environmental Pollutants; | 2018 |
[Reappraisal of metformin : less restrictions and more potential indications].
Topics: Contraindications, Drug; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypoglycemic Agents; Met | 2018 |
Are patients with mild to moderate renal impairment on metformin or other oral anti-hyperglycaemic agents at increased risk of contrast-induced nephropathy and metabolic acidosis after radiocontrast exposure?
Topics: Acidosis; Administration, Oral; Aged; Contrast Media; Diabetes Mellitus, Type 2; Female; Humans; Hyp | 2019 |
[How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
Topics: Contraindications; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Humans; Hypoglycemic Agents; M | 2013 |
Fatal metformin overdose: case report and postmortem biochemistry contribution.
Topics: Acidosis, Lactic; Aged; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdo | 2014 |
[Sitagliptin in the treatment of type 2 diabetes: insights five years after commercialisation].
Topics: Belgium; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Relationship, | 2013 |
Second-line agents for glycemic control for type 2 diabetes: are newer agents better?
Topics: Amputation, Surgical; Blood Glucose; Coronary Artery Disease; Diabetes Complications; Diabetes Melli | 2014 |
Risk of lactic acidosis or elevated lactate concentrations in metformin users with renal impairment: a population-based cohort study.
Topics: Acidosis, Lactic; Adult; Aged; Cohort Studies; Comorbidity; Diabetes Mellitus, Type 2; Female; Human | 2014 |
Incidence of lactic acidosis in patients with type 2 diabetes with and without renal impairment treated with metformin: a retrospective cohort study.
Topics: Acidosis, Lactic; Adolescent; Adult; Aged; Aged, 80 and over; Databases, Factual; Diabetes Mellitus, | 2014 |
Metformin use reduction in mild to moderate renal impairment: possible inappropriate curbing of use based on food and drug administration contraindications.
Topics: Contraindications; Creatinine; Female; Glomerular Filtration Rate; Humans; Hypoglycemic Agents; Male | 2015 |
Incidence and risk factors of postpericardiotomy syndrome requiring medical attention: The Finland postpericardiotomy syndrome study.
Topics: Aged; Body Mass Index; Chi-Square Distribution; Comorbidity; Diabetes Mellitus; Drainage; Erythrocyt | 2015 |
Retrospective analysis of lactic acidosis-related parameters upon and after metformin discontinuation in patients with diabetes and chronic kidney disease.
Topics: Acidosis, Lactic; Adult; Aged; Cohort Studies; Comorbidity; Creatinine; Diabetes Mellitus, Type 2; F | 2016 |
[Chronic kidney diseases, metformin and lactic acidosis].
Topics: Acidosis, Lactic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Metformin; Renal Insuffici | 2016 |
Development, implementation and outcome analysis of semi-automated alerts for metformin dose adjustment in hospitalized patients with renal impairment.
Topics: Acidosis, Lactic; Aged; Algorithms; Automation; Dose-Response Relationship, Drug; Drug Overdose; Fem | 2016 |
Metformin use and risk of lactic acidosis in people with diabetes with and without renal impairment: a cohort study in Denmark and the UK.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Databases, Factual; | 2017 |
Trends in metformin utilisation and dose appropriateness in Australia.
Topics: Diabetes Mellitus, Type 2; Drug Utilization; Glomerular Filtration Rate; Hospitals, Teaching; Humans | 2016 |
Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin.
Topics: Adult; Aged; Asian People; Blood Urea Nitrogen; Creatinine; Diabetes Mellitus, Type 2; Female; Glyca | 2016 |
Association between Metformin Use and Risk of Lactic Acidosis or Elevated Lactate Concentration in Type 2 Diabetes.
Topics: Acidosis, Lactic; Adult; Aged; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Female; Humans; H | 2017 |
Clinical development of metformin extended-release tablets for type 2 diabetes: an overview.
Topics: Biological Availability; Clinical Trials as Topic; Delayed-Action Preparations; Diabetes Mellitus, T | 2008 |
[Toxic metformin-associated acute pancreatitis without kidney failure].
Topics: Acute Disease; Female; Humans; Hypoglycemic Agents; Metformin; Pancreatitis; Renal Insufficiency; Yo | 2008 |
Metformin associated lactic acidosis: incidence and clinical correlation with metformin serum concentration measurements.
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Early | 2011 |
Metformin for patients with diabetes and concomitant renal restrictions--is there an evidence base?
Topics: Diabetes Mellitus, Type 2; Evidence-Based Medicine; Humans; Hypoglycemic Agents; Metformin; Renal In | 2013 |
Inappropriate prescription for metformin.
Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus, Type 2; Health Services Misuse; Heart Failur | 2002 |
[Does a reduced kidney function (creatinine clearance 10-15 ml/min), without acidosis, increase the risk for the rise of lactic acidosis caused by metformin?].
Topics: Acidosis, Lactic; Contraindications; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Diabetic Neph | 2002 |
Metformin and serious adverse effects.
Topics: Acidosis, Lactic; Adverse Drug Reaction Reporting Systems; Aged; Australia; Creatinine; Diabetes Mel | 2004 |
Why hold the metformin?
Topics: Acidosis, Lactic; Age Factors; Aged; Contrast Media; Diabetes Mellitus, Type 2; Humans; Hypoglycemic | 2004 |
Contraindications can damage your health--is metformin a case in point?
Topics: Acidosis, Lactic; Aging; Contraindications; Diabetes Mellitus, Type 2; Heart Diseases; Humans; Hypog | 2005 |
[Prevention of contrast nephropathy; guidelines from the Department Nephrology of the University Medical Centre Groningen].
Topics: Acidosis, Lactic; Contrast Media; Humans; Metformin; Netherlands; Rehydration Solutions; Renal Insuf | 2006 |
Metformin-associated lactic acidosis treated with continuous renal replacement therapy.
Topics: Acidosis, Lactic; Aged; Diabetes Mellitus; Hemodiafiltration; Humans; Hypoglycemic Agents; Male; Met | 2006 |
Use of metformin according to estimated glomerular filtration rate: the threshold and the equation are important.
Topics: Aged; Creatinine; Diabetes Mellitus, Type 2; Female; Glomerular Filtration Rate; Humans; Metformin; | 2007 |
Metformin-associated lactic acidosis in patients with renal impairment solely due to drug accumulation?
Topics: Acidosis, Lactic; Aged; Diabetic Nephropathies; Female; Humans; Hypoglycemic Agents; Male; Metformin | 2008 |
Metformin-associated lactic acidosis following contrast media-induced nephrotoxicity.
Topics: Acidosis, Lactic; Angiography, Digital Subtraction; Blood Gas Analysis; Contrast Media; Diabetes Mel | 2008 |
Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes-related complications.
Topics: Amputation, Surgical; Blindness; Cardiovascular Diseases; Computer Simulation; Diabetes Complication | 2008 |
Metformin treatment in NIDDM patients with mild renal impairment.
Topics: Aged; Case-Control Studies; Creatinine; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agen | 1996 |
Metformin and contrast media: where is the conflict?
Topics: Acidosis, Lactic; Contraindications; Contrast Media; Diabetes Mellitus, Type 2; Drug Interactions; H | 1998 |
Metformin hydrochloride in patients undergoing myelography.
Topics: Contrast Media; Drug Interactions; Humans; Hypoglycemic Agents; Metformin; Myelography; Renal Insuff | 2002 |
Frequency of inappropriate metformin prescriptions.
Topics: Contraindications; Drug Utilization Review; Heart Failure; Humans; Hypoglycemic Agents; Metformin; R | 2002 |